Parallel synthesis of condensed pyrimidine-thiones and their antitumor activities

doi:10.21203/rs.3.rs-2121388/v1

Download PDF

Research Article

Parallel synthesis of condensed pyrimidine-thiones and their antitumor activities

https://doi.org/10.21203/rs.3.rs-2121388/v1

This work is licensed under a CC BY 4.0 License

You are reading this latest preprint version

Herein we studied the formation of thiones via C=O group conversion into the C=S functional group-based tricyclic pyrimidinone systems using Lawesson’s reagent and phosphorus pentasulfide as thionation agents. Naturally-occurring alkaloids deoxyvasicinone and mackinazolinone were selected as templates for the modification of furo[2,3-d]pyrimidinone and pyrrolo[2,3-d]pyrimidinone scaffold. Research work was performed under the combinatorial and parallel synthesis of pyrimidine-based small molecules, along with a one-pot reaction strategy. All synthesized 54 novel pyrimidine-thiones were elucidated by ¹H-NMR, ¹³C-NMR, and HRMS analysis. In addition, both series of thiones were evaluated for their antitumor activity against three types of the human cancer cell: cervical HeLa, breast MCF-7, and colon HT-29 lines. Compound with azepine fragment 13aa (1-methyl-2-(4-(trifluoromethyl)phenyl)-1,6,7,8,9,10-hexahydro-4H-pyrrolo[2',3':4,5]pyrimido[1,2-a]azepine-4-thione) was most active derivative (IC₅₀=2.09±0.22 µM) against the HT-29 cell line.

Thiones

parallel synthesis

furo[2

3-d]pyrimidinthione

pyrrolo[2

3-d]pyrimidinthione

antitumor activity

Clinical trials show that most medical drugs which are used in cancer chemotherapy fail to produce satisfactory outcomes because of poor selectivity, efficiency, or various side effects [1–3]. Therefore, there is still a need to improve the drug development process [4, 5]. Pyrimidine-based small molecules [6] are a group of chemotherapeutic agents [7], where include 5-FU, capecitabine [8], decitabine [9], gemcitabine [10], raltitrexed [11], floxuridine [12], tegafur [13], and others [14]. These anticancer agents induce apoptosis while progressing via the cell cycle by inhibiting appropriate targets. In addition, pyrimidine-based small molecules are also included in system nitrogen, oxygen, and sulfur heteroatoms.

Organosulfur compounds are components or fragments in pyrimidine-based small molecules [15]. Herein, among the organosulfur derivatives (both natural and synthetic) thio-analogs of ketones are important scaffolds from chemical, medical [16], and industrial [17] points of view. Literature reports show that most organosulfur derivatives are found as potential inhibitors of various major enzymes, indicating the importance of these class compounds in medicinal chemistry [18–20].

Naturally-occurring alkaloids deoxyvasicinone [21, 22] and mackinazolinone [23] are isolated from the plants Adhatoda vasica and Mackilaya subulata Philipson, respectively. These pyrimidine-based derivatives have demonstrated potential biological properties [24–26]. The tricyclic deoxyvasicinone system is part of other biologically important alkaloids including isaindigotone [27], tryptanthrin [28], and luotonin A [29], while mackinazolinone is part of rutaecarpine [30] and evodiamine [31], respectively (Fig. 1). Our research group performed large studies on the synthetic analogs of deoxyvasicinone and mackinazolinone, which containing carbonyl (C = O) group in the pyrimidine ring [32–38]. Results revealed that several modified analogs of these alkaloids exhibited satisfactory higher antiproliferative activity against a panel of human cancer cell lines [32, 39].

Spurred by this preliminary success, we proceeded to examine the combinatorial and parallel transformation of furo- and pyrrolopyrimidinones under thionation agents. An important field of research in medicinal and organic chemistry involves heterocyclic thiones forming the backbone of more complex organic compounds, especially those using other sites for their attachment to specific types of rapidly forming molecules [40, 41]. Therefore, herein we studied the formation of thiones via C = O group conversion into the C = S functional group based tricyclic pyrimidinone system using Lawesson’s reagent [42–44] and phosphorus pentasulfide [45] as thionation agents. In addition, all synthesized thio-compounds were evaluated for their antitumor activity on human cancer cell cervical HeLa, breast MCF-7, and colon HT-29 lines.

2.1. Chemistry

The thionation of bicyclic pyrimidines or related compounds with Lawesson’s reagent has been presented earlier [46, 47]. Other pathways have also been reported in the literature for the C = O group conversion into C = S [48, 49]. However, we turned our attention toward a milder route in order to perform systematic combinatorial and parallel thionation of the diverse molecular systems, along with their evaluation of the antitumor activity.

The formation of furo[2,3-d]pyrimidinone 6a-6aa and pyrrolo[2,3-d]pyrimidinone 11a-11aa intermediates were described in our recently reported research (Scheme 1) [50]. Proceeding from this research we have studied a parallel thionation process of the obtained pyrimidinones 6a-6aa and 11a-11aa. First, in an example of compounds 6g and 11g, thionation conditions were investigated. Subjecting pyrimidinones 6g and 11g to reflux in the presence of Lawesson’s reagent in toluene or dioxane results in conversion of the oxygen of the carbonyl group convers to sulfur; under these conditions, the products 12g and 13g are obtained in 56 and 88% yields, respectively (Table 1). In our research, we also used other thionation agents in order to convert C = O to C = S (for example with P₂S₅). All reactions using this reagent were performed in dioxane or toluene. Unfortunately, all efforts to introduce “thion” functionality into the tricyclic annulated system were not similar in both series of pyrimidinones. Herein, Lawesson’s reagent was more suitable for the thionation of pyrrolo[2,3-d]pyrimidinone (for compound 11g), while using the P₂S₅ afforded a final thion-product (12g) of furo[2,3-d]pyrimidinone derivatives yielded in a quit good yield (74%, Table 1).

The direct one-pot formation of target thiones (12g and 13g) from five-membered 2-amino esters (4c and 10c) was also investigated (Scheme 2). When 2-amino esters are subjected to condensation in the presence of lactam (5a) and POCl₃ (dioxane used as reaction solvent) leads to intermediates (6g and 11g) after 3–4 hrs; the addition of Lawesson’s reagent into the reaction mixture followed by a reaction time of 4 h, gives thiones 12g and 13g.

As discussed above, pyrimidine-thiones were produced in two cases, where dioxane or toluene and only dioxane (in the one-pot reaction, Scheme 2) were used as a solvent. Although we performed direct one-pot synthesis (from mono-cyclic esters), increased yields were observed in the synthetic pathways from the furo[2,3-d]pyrimidinone 6g and pyrrolo[2,3-d]pyrimidinone 11g intermediates. The direct one-pot synthesis from ester’s desired thiones was obtained at a low yield, as well as workup procedures were a bit difficult, because of the formed side products. However, further development of this method may serve to obtain pyrimidine-thiones via a simple pathway.

Thus, the combinatorial and parallel thionation of pyrimidinones was achieved using Lawesson’s reagent toward the pyrrolo[2,3-d]pyrimidinthiones (Scheme 3) and P₂S₅ in the furo[2,3-d]pyrimidinthiones (Scheme 4), respectively.

It should be noted that using a P₂S₅ in the furo[2,3-d]pyrimidinthiones formation, we observed the ability of substituents in the yield of final products. The methyl group at C-2 or C-2/C-3 positions of the furan ring influence to form of thiones in lower yield (18–44%), followed to increase compounds yield (up to 74%) by introducing a phenyl substituent at position C-2. Introduction of the 4-substituted-phenyl group at C-2 gave desired thiones up to 99%. Therefore, phosphorus pentasulfide was found as a convenient thionation agent on furo[2,3-d]pyrimidinthiones 12j-12aa. Furthermore, using a P₂S₅ in the furo[2,3-d]pyrimidinthiones, only products were formed during checking at TLC (Thin-layer chromatography), while with Lawesson’s reagent was formed several bi-products. In the case of pyrrolo[2,3-d]pyrimidinthiones, final products were yielded up to 99% using Lawesson’s reagent as a thionation agent, and no bi-products were observed.

All synthesized furo[2,3-d]pyrimidinthiones (12a-12aa) were elucidated by ¹H-NMR, ¹³C-NMR, and HRMS as described in the experimental part, as well as X-ray analysis for derivative 12c (Fig. 2).

2.2. Antitumor activity

All the synthesized condensed pyrimidin-thiones 12a-12aa and 13a-13aa were tested for their cytotoxic activity against three types of human cancer cell: cervical HeLa, breast MCF-7, and colon HT-29 lines using the MTT method (Table 2). Doxorubicin (DOX) is used as a reference drug. As shown in Table 2, furo[2,3-d]pyrimidinthiones were inactive, and showed IC₅₀ values ≥ 50 µM, except of derivatives 12e (40.45 ± 2.03) and 12g (17.68 ± 0.83) on HT-29 cell lines. In general, among the furopyrimidinthione series, there was no real trend between the various side-rings and substituents on the pyrimidinone system concerning the activity. However, several pyrrolo[2,3-d]pyrimidinthiones demonstrated weak to high cytotoxic activity against selected human cancer cell lines. Among the twenty-seven synthesized pyrrolo[2,3-d]pyrimidinthione derivatives, fourteen samples were quite active with IC₅₀ values ≤ 50. In addition, results revealed that among the human cancer cell lines evaluated, the HT-29 cancer cell line was more sensitive. Derivatives 13j, 13l, 13o, 13r, 13t, 13z, and 13aa have exhibited higher activity with IC₅₀ values ranging from 2.09 ± 0.22 to 9.84 ± 0.88 µM. All these compounds contain phenyl or 4-substituted phenyl group at position C-2. It was observed that the increase of methylene groups effect cytotoxic activity (Fig. 3). For example, a compound with azepine fragment 13aa (1-methyl-2-(4-(trifluoromethyl)phenyl)-1,6,7,8,9,10-hexahydro-4H-pyrrolo[2',3':4,5]pyrimido[1,2-a]azepine-4-thione) was most active derivative (IC₅₀ = 2.09 ± 0.22 µM) against the HT-29 cell line (Fig. 3). Therefore, a further detailed study is needed on this way, where obtained leading compounds may serve a good candidate as anticancer agents.

We have designed and synthesized novel 2-substituted furo[2,3-d]pyrimidinthione and pyrrolo[2,3-d]pyrimidinthione derivatives under combinatorial and parallel synthesis strategy. This heterocyclic system is furan/pyrrole analogs of the naturally-occurring deoxyvasicinone mackinazolinone alkaloids. In general, two thionation agents were used to study systematic thionation. Results revealed that Lawesson’s reagent was more suitable for the thionation of pyrrolo[2,3-d]pyrimidinones, while using P₂S₅ afforded a final thion-products of furo[2,3-d]pyrimidinones in a quit good yield. All of the newly designed thiones were evaluated against the human cancer cell lines Hela, MCF-7, and HT-29. The furo[2,3-d]pyrimidinthione series were not demonstrated antitumor activity against selected cell lines. However, several pyrrolo[2,3-d]pyrimidinthiones showed weak to high cytotoxic activity. Among the twenty-seven synthesized pyrrolo[2,3-d]pyrimidinthione derivatives, fourteen samples were quite active with IC₅₀ values ≤ 50. Azepine containing derivative 13aa (1-methyl-2-(4-(trifluoromethyl)phenyl)-1,6,7,8,9,10-hexahydro-4H-pyrrolo[2',3':4,5]pyrimido[1,2-a]azepine-4-thione) displayed high (IC₅₀ = 2.09 ± 0.22 µM) antitumor activity against the HT-29 cell line, which further modification could be serve as leading compound in anticancer drug design investigations.

4.1. Chemistry

Materials and methods

All reagents and solvents were purchased from Sigma and used without further purification. Thin-layer chromatography (TLC) was performed on glass plates coated with silica gel (Qingdao Haiyang Chemical Co., G60F-254) and visualized by UV light (254 nm). The products were purified by column chromatography over silica gel (Qingdao Haiyang Chemical Co., 200–300 mesh). Melting points were determined on a Buchi B-540 apparatus and were uncorrected. Nuclear magnetic resonance (NMR) spectra were recorded with a Varian 400 MHz NMR spectrometer in CDCl₃, using TMS as an internal standard. High-resolution mass spectra (HRMS) were recorded on an AB SCIEX QSTAR Elite quadrupole time-of-flight mass spectrometry.

General procedure for synthesis of compounds 12a-12aa.

The solution of 1 mmol furo[2,3-d]pyrimidinones (6a-6aa) in 10 mL of dried toluene or dioxane was stirred under reflux with 1.1 mmol of phosphorus pentasulfide (P₂S₅). After 4 h, the reaction mixture was cooled to 20–25°C, the solvent removed under reduced pressure and the residue column chromatographed using petroleum ether and ethyl acetate as an eluent to give solid thiones 12a-12aa.

2-Methyl-7,8-dihydrofuro[2,3- d ]pyrrolo[1,2- a ]pyrimidine-4(6 H )-thione (12a). Yield 25%, yellow solid, m.p.159–160°C. ¹H NMR (400 MHz, CDCl₃) δ 6.62 (s, 1H), 4.52 (t, J = 8.0 Hz, 2H), 3.32 (t, J = 8.1 Hz, 2H), 2.42 (s, 3H), 2.41–2.32 (m, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 176.57, 159.91, 159.64, 154.09, 120.54, 104.06, 52.50, 33.02, 19.12, 14.09; HRMS (ESI): calcd for C₁₀H₁₀N₂OS [M + H]⁺: 207.0592, found 207.0592.

2-Methyl-6,7,8,9-tetrahydro-4 H -furo[2,3- d ]pyrido[1,2- a ]pyrimidine-4-thione (12b). Yield 18%, yellow solid, m.p.139–140°C. ¹H NMR (400 MHz, CDCl₃) δ 6.61 (s, 1H), 4.57 (t, J = 6.2 Hz, 2H), 3.07 (t, J = 6.8 Hz, 2H), 2.39 (s, 3H), 2.09–2.00 (m, 2H), 1.99–1.90 (m, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 179.58, 157.43, 156.87, 153.88, 121.18, 104.70, 48.83, 32.63, 22.37, 18.72, 13.98; HRMS (ESI): calcd for C₁₁H₁₂N₂OS [M + H]⁺: 221.0749, found 221.0749.

2-Methyl-7,8,9,10-tetrahydrofuro[2',3':4,5]pyrimido[1,2- a ]azepine-4(6 H )-thione (12c). Yield 40%, yellow solid, m.p.119–120°C. ¹H NMR (400 MHz, CDCl₃) δ 6.61 (s, 1H), 5.09 (t, J = 5.0Hz, 2H), 3.20 (t, J = 6.8Hz, 2H), 2.41 (s, 3H), 1.93–1.81 (m, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 180.11, 161.19, 157.26, 154.23, 121.06, 105.24, 49.83, 38.07, 29.14, 26.15, 24.95, 14.02. HRMS (ESI): calcd for C₁₂H₁₄N₂OS [M + H]⁺: 235.0905, found 235.0904.

2,3-Dimethyl-7,8-dihydrofuro[2,3- d ]pyrrolo[1,2- a ]pyrimidine-4(6 H )-thione (12d). Yield 26%, yellow solid, m.p.223–224°C. ¹H NMR (400 MHz, CDCl₃) δ 4.50 (t, J = 7.5 Hz, 2H), 3.29 (t, J = 8.1 Hz, 2H), 2.42 (s, 3H), 2.38–2.29 (m, 5H); ¹³C NMR (101 MHz, CDCl₃) δ 177.32, 159.64, 159.43, 148.96, 118.90, 113.60, 52.15, 32.99, 18.96, 11.48, 9.74; HRMS (ESI): calcd for C₁₁H₁₂N₂OS [M + H]⁺: 221.0749, found 221.0749.

2,3-Dimethyl-6,7,8,9-tetrahydro-4 H -furo[2,3- d ]pyrido[1,2- a ]pyrimidine-4-thione (12e). Yield 44%, yellow solid, m.p. 179–180°C. ¹H NMR (400 MHz, CDCl₃) δ 4.58 (t, J = 6.2 Hz, 2H), 3.06 (t, J = 6.8 Hz, 2H), 2.45 (s, 3H), 2.32 (s, 3H), 2.10–2.01 (m, 2H), 1.99–1.90 (m, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 180.49, 157.39, 156.71, 148.78, 119.64, 113.92, 48.02, 32.69, 22.48, 18.73, 11.55, 10.17; HRMS (ESI): calcd for C₁₂H₁₄N₂OS [M + H]⁺: 235.0905, found 235.0906.

2,3-Dimethyl-7,8,9,10-tetrahydrofuro[2',3':4,5]pyrimido[1,2- a ]azepine-4(6 H )-thione (12f). Yield 38%, yellow solid, m.p.114–115°C. ¹H NMR (400 MHz, CDCl₃) δ 5.08 (t, 2H), 3.17 (t, J = 6.8Hz, 2H), 2.44 (s, 3H), 2.31 (t, J = 5.0Hz, 3H), 1.92–1.79 (m, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 180.90, 160.93, 157.20, 149.01, 119.40, 114.13, 48.66, 38.06, 29.06, 26.05, 24.93, 11.52, 10.06; HRMS (ESI): calcd for C₁₃H₁₆N₂OS [M + H]⁺: 249.1062, found 249.1062.

2-Phenyl-7,8-dihydrofuro[2,3- d ]pyrrolo[1,2- a ]pyrimidine-4(6 H )-thione (12g). Yield 74%, yellow solid, m.p. 234.5-235.7°C. ¹H NMR (400 MHz, CDCl₃) δ 7.79 (d, J = 7.2 Hz, 2H), 7.44 (t, J = 7.4 Hz, 2H), 7.37 (t, J = 7.3 Hz, 1H), 7.25 (s, 1H), 4.55 (t, J = 7.4 Hz, 2H), 3.36 (t, J = 8.1 Hz, 2H), 2.39 (dt, J = 15.7, 7.9 Hz, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 177.09, 160.62, 159.95, 154.38, 129.14, 128.99, 128.97, 124.66, 121.17, 102.38, 52.57, 33.16, 19.10; HRMS (ESI): calcd for C₁₅H₁₃N₂OS [M + H]⁺: 269.0749, found 269.0750.

2-Phenyl-6,7,8,9-tetrahydro-4 H -furo[2,3- d ]pyrido[1,2- a ]pyrimidine-4-thione (12h). Yield 73%, yellow solid, m.p. 199.4-200.2°C. ¹H NMR (400 MHz, CDCl₃) δ 7.78 (d, J = 7.4 Hz, 2H), 7.43 (t, J = 7.5 Hz, 2H), 7.36 (t, J = 7.3 Hz, 1H), 7.25 (s, 1H), 4.60 (t, J = 6.1 Hz, 2H), 3.13 (t, J = 6.8 Hz, 2H), 2.13–2.05 (m, 2H), 2.03–1.94 (m, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 180.06, 157.66, 154.05, 129.06, 128.92, 128.89, 124.64, 121.67, 103.03, 48.99, 32.77, 22.37, 18.71, 18.39; HRMS (ESI): calcd for C₁₆H₁₅N₂OS [M + H]⁺: 283.0905, found 283.0908.

2-Phenyl-7,8,9,10-tetrahydrofuro[2',3':4,5]pyrimido[1,2- a ]azepine-4(6 H )-thione (12i). Yield 23%, yellow solid, m.p. 190.6-191.8°C. ¹H NMR (400 MHz, CDCl₃) δ 7.79 (d, J = 7.3 Hz, 2H), 7.44 (t, J = 7.4 Hz, 2H), 7.37 (t, J = 7.3 Hz, 1H), 7.23 (s, 1H), 5.11 (t, J = 4.1 Hz, 2H), 3.24 (t, J = 6.4 Hz, 2H), 1.95–1.85 (s, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 180.61, 161.93, 157.51, 154.44, 129.15, 128.96, 124.96, 124.71, 121.59, 103.62, 49.90, 38.21, 29.14, 26.13, 24.93; HRMS (ESI): calcd for C₁₆H₁₅N₂OS [M + H]⁺: 297.1062, found 297.1064.

2-(4-Fluorophenyl)-7,8-dihydrofuro[2,3- d ]pyrrolo[1,2- a ]pyrimidine-4(6 H )-thione (12j). Yield 99%, yellow solid, m.p255.5-257.4.°C. ¹H NMR (400 MHz, CDCl₃) δ 7.71 (dd, J = 8.6, 5.3 Hz, 2H), 7.11 (t, J = 8.6 Hz, 2H), 7.01 (s, 1H), 4.21 (t, J = 7.3 Hz, 2H), 3.21 (t, J = 8.0 Hz, 2H), 2.40–2.27 (m, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 165.22, 164.02, 161.54, 160.89, 157.74, 151.40, 126.18, 126.10, 116.09, 115.87, 107.30, 99.89, 46.84, 32.39, 19.62. HRMS (ESI): calcd for C₁₅H₁₂FN₂OS [M + H]⁺: 287.0654, found 287.0647.

2-(4-Fluorophenyl)-6,7,8,9-tetrahydro-4 H -furo[2,3- d ]pyrido[1,2- a ]pyrimidine-4-thione (12k). Yield 99%, yellow solid, m.p. 220.9–222.0°C. ¹H NMR (400 MHz, CDCl₃) δ 7.73 (dd, J = 8.1, 5.6 Hz, 2H), 7.15 (s, 1H), 7.11 (t, J = 8.5 Hz, 2H), 4.59 (t, J = 6.1 Hz, 2H), 3.12 (t, J = 6.7 Hz, 2H), 2.14–1.94 (m, 4H); ¹³C NMR (101 MHz, CDCl₃) δ 180.07, 164.32, 161.83, 157.73, 153.11, 126.61, 126.61, 125.27, 121.65, 116.20, 115.98, 102.72, 49.04, 32.80, 22.38, 18.71. HRMS (ESI): calcd for C₁₆H₁₄FN₂OS [M + H]⁺: 301.0811, found 301.0810.

2-(4-Fluorophenyl)-7,8,9,10-tetrahydrofuro[2',3':4,5]pyrimido[1,2- a ]azepine-4(6 H )-thione (12l). Yield 99%, yellow solid, m.p. 201.6-202.5°C. ¹H NMR (400 MHz, CDCl₃) δ 7.76 (dd, J = 8.7, 5.3 Hz, 2H), 7.16 (s, 1H), 7.13 (t, J = 8.8 Hz, 2H), 5.15–5.06 (m, 2H), 3.23 (t, J = 5.0 Hz, 2H), 1.96–1.83 (m, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 180.57, 164.37, 161.99, 157.46, 153.48, 126.64, 125.30, 121.53, 116.25, 116.03, 103.29, 49.89, 38.17, 29.10, 26.08, 24.88; HRMS (ESI): calcd for C₁₇H₁₆FN₂OS [M + H]⁺: 315.0967, found 315.0961.

2-(4-Chlorophenyl)-7,8-dihydrofuro[2,3- d ]pyrrolo[1,2- a ]pyrimidine-4(6 H )-thione (12m). Yield 44%, yellow solid, m.p. 243.3-244.4°C. ¹H NMR (400 MHz, CDCl₃) δ 7.66 (d, J = 8.5 Hz, 2H), 7.38 (d, J = 8.5 Hz, 2H), 7.06 (s, 1H), 4.22 (t, J = 7.3 Hz, 2H), 3.21 (t, J = 8.0 Hz, 2H), 2.39–2.28 (m, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 165.31, 161.14, 157.69, 151.16, 134.32, 129.10, 127.92, 125.47, 107.30, 100.70, 46.86, 32.42, 19.61. HRMS (ESI): calcd for C₁₅H₁₂ClN₂OS [M + H]⁺: 303.0359, found 303.0351.

2-(4-Chlorophenyl)-6,7,8,9-tetrahydro-4 H -furo[2,3- d ]pyrido[1,2- a ]pyrimidine-4-thione (12n). Yield 99%, yellow solid, m.p. 220.6–222.0°C. ¹H NMR (400 MHz, CDCl₃) δ 7.71 (d, J = 8.5 Hz, 2H), 7.41 (d, J = 8.5 Hz, 2H), 7.24 (s, 1H), 4.60 (t, J = 6.2 Hz, 2H), 3.14 (t, J = 6.8 Hz, 2H), 2.10 (p, J = 6.2 Hz, 2H), 1.99 (p, J = 6.6 Hz, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 180.24, 157.94, 157.75, 152.91, 134.95, 129.21, 127.44, 125.84, 121.62, 103.54, 49.05, 32.82, 22.38, 18.71. HRMS (ESI): calcd for C₁₆H₁₄ClN₂OS [M + H]⁺: 317.0515, found 317.0508.

2-(4-Chlorophenyl)-7,8,9,10-tetrahydrofuro[2',3':4,5]pyrimido[1,2- a ]azepine-4(6 H )-thione (12o). Yield 99%, yellow solid, m.p. 207.3-208.3°C. ¹H NMR (400 MHz, CDCl₃) δ 7.67 (d, J = 8.6 Hz, 2H), 7.39 (d, J = 8.6 Hz, 2H), 7.06 (s, 1H), 4.46–4.36 (m, 2H), 3.14–3.05 (m, 2H), 1.94–1.73 (m, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 163.12, 161.75, 158.81, 151.12, 134.35, 129.12, 127.93, 125.52, 106.70, 101.05, 42.87, 37.64, 29.54, 27.49, 24.95. HRMS (ESI): calcd for C₁₇H₁₆ClN₂OS [M + H]⁺: 331.0672, found 331.0665.

2-(4-Bromophenyl)-7,8-dihydrofuro[2,3- d ]pyrrolo[1,2- a ]pyrimidine-4(6 H )-thione (12p). Yield 99%, yellow solid, m.p. 270.8-272.3°C. ¹H NMR (400 MHz, CDCl₃) δ 7.60 (d, J = 8.4 Hz, 2H), 7.54 (d, J = 8.6 Hz, 2H), 7.08 (s, 1H), 4.22 (t, J = 7.4 Hz, 2H), 3.21 (t, J = 8.0 Hz, 2H), 2.40–2.27 (m, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 165.33, 161.19, 157.68, 151.18, 132.04, 128.34, 125.70, 122.50, 107.31, 100.82, 46.87, 32.43, 19.60. HRMS (ESI): calcd for C₁₅H₁₂BrN₂OS [M + H]⁺: 346.9854, found 346.9841.

2-(4-Bromophenyl)-6,7,8,9-tetrahydro-4 H -furo[2,3- d ]pyrido[1,2- a ]pyrimidine-4-thione (12q). Yield 89%, yellow solid, m.p. 234.4-235.7°C. ¹H NMR (400 MHz, CDCl₃) δ 7.60 (d, J = 8.4 Hz, 2H), 7.54 (d, J = 8.6 Hz, 2H), 7.08 (s, 1H), 4.08 (t, J = 6.0 Hz, 2H), 3.02 (t, J = 6.6 Hz, 2H), 2.07–1.90 (m, 4H); ¹³C NMR (101 MHz, CDCl₃) δ 163.41, 159.00, 157.02, 150.80, 132.03, 128.38, 125.72, 122.46, 106.66, 100.91, 42.57, 31.92, 22.02, 19.12. HRMS (ESI): calcd for C₁₆H₁₄BrN₂OS [M + H]⁺: 361.0010, found 361.0001.

2-(4-Bromophenyl)-7,8,9,10-tetrahydrofuro[2',3':4,5]pyrimido[1,2- a ]azepine-4(6 H )-thione (12r). Yield 99%, yellow solid, m.p. 213.5-214.9°C. ¹H NMR (400 MHz, CDCl₃) δ 7.64 (d, J = 8.4 Hz, 2H), 7.57 (d, J = 8.5 Hz, 2H), 7.23 (s, 1H), 5.15–5.06 (m, 2H), 3.28–3.20 (m, 2H), 1.96–1.83 (m, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 180.71, 162.22, 157.56, 153.27, 132.18, 127.85, 126.06, 123.24, 121.48, 104.19, 49.89, 38.20, 29.10, 26.08, 24.87. HRMS (ESI): calcd for C₁₇H₁₆BrN₂OS [M + H]⁺: 375.0167, found 375.0161.

2-( p -Tolyl)-7,8-dihydrofuro[2,3- d ]pyrrolo[1,2- a ]pyrimidine-4(6 H )-thione (12s). Yield 73%, yellow solid, m.p. 262.9-264.3°C. ¹H NMR (400 MHz, CDCl₃) δ 7.64 (d, J = 8.1 Hz, 2H), 7.22 (d, J = 8.0 Hz, 2H), 7.02 (s, 1H), 4.21 (t, J = 7.4 Hz, 2H), 3.20 (t, J = 8.0 Hz, 2H), 2.37 (s, 3H), 2.36–2.26 (m, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 165.08, 160.55, 157.82, 152.59, 138.65, 129.53, 126.71, 124.24, 107.34, 99.42, 46.81, 32.36, 21.33, 19.63. HRMS (ESI): calcd for C₁₆H₁₅N₂OS [M + H]⁺: 283.0905, found 283.0898.

2-( p -Tolyl)-6,7,8,9-tetrahydro-4 H -furo[2,3- d ]pyrido[1,2- a ]pyrimidine-4-thione (12t). Yield 99%, yellow solid, m.p. 202.0-203.6°C. ¹H NMR (400 MHz, CDCl₃) δ 7.69 (d, J = 8.0 Hz, 2H), 7.25 (d, J = 7.8 Hz, 2H), 7.20 (s, 1H), 4.61 (t, J = 6.1 Hz, 2H), 3.14 (t, J = 6.7 Hz, 2H), 2.39 (s, 3H), 2.10 (p, J = 6.2 Hz, 2H), 1.99 (p, J = 6.5 Hz, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 179.87, 157.56, 157.42, 154.42, 139.32, 129.62, 126.22, 124.64, 121.79, 102.23, 49.00, 32.77, 22.40, 21.40, 18.74. HRMS (ESI): calcd for C₁₇H₁₇N₂OS [M + H]⁺: 297.1062, found 283.0898.

2-( p -tolyl)-7,8,9,10-tetrahydrofuro[2',3':4,5]pyrimido[1,2- a ]azepine-4(6 H )-thione (12u). Yield 99%, yellow solid, m.p. 185.6-186.6°C. ¹H NMR (400 MHz, CDCl₃) δ 7.69 (d, J = 8.0 Hz, 2H), 7.25 (d, J = 8.2 Hz, 2H), 7.18 (s, 1H), 5.16–5.07 (m, 2H), 3.27–3.20 (m, 2H), 2.39 (s, 3H), 1.95–1.83 (m, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 180.36, 161.68, 157.35, 154.77, 139.38, 129.64, 126.21, 124.66, 121.66, 102.77, 49.87, 38.16, 29.12, 26.11, 24.91, 21.40. HRMS (ESI): calcd for C₁₈H₁₉N₂OS [M + H]⁺: 311.1218, found 311.1211.

2-(4-Methoxyphenyl)-7,8-dihydrofuro[2,3- d ]pyrrolo[1,2- a ]pyrimidine-4(6 H )-thione (12v). Yield 99%, yellow solid, m.p. 219.2–221.0°C. ¹H NMR (400 MHz, CDCl₃) δ 7.72 (d, J = 8.7 Hz, 2H), 7.11 (s, 1H), 6.97 (d, J = 8.7 Hz, 2H), 4.55 (t, J = 7.5 Hz, 2H), 3.86 (s, 3H), 3.35 (t, J = 8.0 Hz, 2H), 2.39 (p, J = 7.8 Hz, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 176.63, 160.42, 160.11, 159.69, 154.60, 126.23, 121.77, 121.36, 114.45, 100.56, 55.38, 52.54, 33.08, 19.09. HRMS (ESI): calcd for C₁₆H₁₅N₂O₂S [M + H]⁺: 299.0854, found 299.0847.

2-(4-Methoxyphenyl)-6,7,8,9-tetrahydro-4 H -furo[2,3- d ]pyrido[1,2- a ]pyrimidine-4-thione (12w). Yield 99%, yellow solid, m.p. 206.6-207.6°C. ¹H NMR (400 MHz, CDCl₃) δ 7.74 (d, J = 8.8 Hz, 2H), 7.13 (s, 1H), 6.97 (d, J = 8.8 Hz, 2H), 4.62 (t, J = 6.2 Hz, 2H), 3.86 (s, 3H), 3.14 (t, J = 6.8 Hz, 2H), 2.10 (p, J = 6.2 Hz, 2H), 1.99 (p, J = 6.6 Hz, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 179.69, 160.43, 157.49, 157.17, 154.39, 126.28, 121.97, 121.78, 114.44, 101.26, 55.38, 49.00, 32.76, 22.42, 18.76. HRMS (ESI): calcd for C₁₇H₁₇N₂O₂S [M + H]⁺: 313.1011, found 313.1002.

2-(4-Methoxyphenyl)-7,8,9,10-tetrahydrofuro[2',3':4,5]pyrimido[1,2- a ]azepine-4(6 H )-thione (12x). Yield 99%, yellow solid, m.p. 191.8-193.3°C. ¹H NMR (400 MHz, CDCl₃) δ 7.72 (d, J = 8.8 Hz, 2H), 7.08 (s, 1H), 6.96 (d, J = 8.8 Hz, 2H), 5.15–5.07 (m, 2H), 3.85 (s, 3H), 3.27–3.19 (m, 2H), 1.94–1.83 (m, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 180.10, 161.44, 160.42, 157.24, 154.66, 126.26, 121.77, 121.72, 114.43, 101.75, 55.37, 49.87, 38.14, 29.12, 26.10, 24.91. HRMS (ESI): calcd for C₁₈H₁₉N₂O₂S [M + H]⁺: 327.1167, found 327.1158.

2-(4-(Trifluoromethyl)phenyl)-7,8-dihydrofuro[2,3- d ]pyrrolo[1,2- a ]pyrimidine-4(6 H )-thione (12y). Yield 99%, yellow solid, m.p. 237.7-238.9°C. ¹H NMR (400 MHz, CDCl₃) δ 7.86 (d, J = 8.2 Hz, 2H), 7.69 (d, J = 8.2 Hz, 2H), 7.35 (s, 1H), 4.54 (t, J = 7.4 Hz, 2H), 3.38 (t, J = 8.1 Hz, 2H), 2.41 (p, J = 8.0 Hz, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 177.43, 161.38, 160.24, 152.44, 132.11, 130.42, 125.94, 124.64, 122.49, 120.86, 104.35, 52.58, 33.19, 18.99. HRMS (ESI): calcd for C₁₆H₁₂F₃N₂OS [M + H]⁺: 337.0622, found 337.0613.

2-(4-(Trifluoromethyl)phenyl)-6,7,8,9-tetrahydro-4 H -furo[2,3- d ]pyrido[1,2- a ]pyrimidine-4-thione (12z). Yield 99%, yellow solid, m.p. 224.8-226.4°C. ¹H NMR (400 MHz, CDCl₃) δ 7.88 (d, J = 8.2 Hz, 2H), 7.69 (d, J = 8.2 Hz, 2H), 7.37 (s, 1H), 4.60 (t, J = 6.1 Hz, 2H), 3.15 (t, J = 6.7 Hz, 2H), 2.11 (p, J = 6.1 Hz, 2H), 2.00 (p, J = 6.7 Hz, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 180.59, 158.44, 158.02, 152.24, 132.15, 130.42, 125.94, 124.70, 122.50, 121.46, 105.14, 49.08, 32.87, 22.36, 18.68. HRMS (ESI): calcd for C₁₇H₁₄F₃N₂OS [M + H]⁺: 351.0779, found 351.0770.

2-(4-(Trifluoromethyl)phenyl)-7,8,9,10-tetrahydrofuro[2',3':4,5]pyrimido[1,2- a ]azepine-4(6 H )-thione (12aa). Yield 99%, yellow solid, m.p. 178.6-180.2°C. ¹H NMR (400 MHz, CDCl₃) δ 7.85 (d, J = 8.2 Hz, 2H), 7.68 (d, J = 8.2 Hz, 2H), 7.19 (s, 1H), 4.48–4.37 (m, 2H), 3.15–3.06 (m, 2H), 1.94–1.74 (m, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 163.44, 162.30, 158.77, 150.52, 132.62, 129.96, 125.88, 124.35, 122.57, 106.67, 102.68, 42.91, 37.68, 29.53, 27.47, 24.92. HRMS (ESI): calcd for C₁₈H₁₆F₃N₂OS [M + H]⁺: 365.0935, found 365.0929.

General procedure for synthesis of compounds 13a-13aa.

The solution of 1 mmol pyrrolo[2,3-d]pyrimidinones (11a-11aa) in 10 mL of dried toluene or dioxane was stirred under reflux with 0.6 mmol of Lawesson’s reagent. After 4 h (in 8–12 h for dioxane), the reaction mixture was cooled to 20–25°C, the solvent removed under reduced pressure and the residue column chromatographed using petroleum ether and ethyl acetate as an eluent to give solid thiones 13a-13aa.

1,2-Dimethyl-1,6,7,8-tetrahydro-4 H -dipyrrolo[1,2- a:2',3'-d]pyrimidine-4-thione (13a). Yield 77%, yellow solid, m.p. 272–273°C. ¹H NMR (400 MHz, CDCl₃) δ 6.55 (s, 1H), 4.54 (t, J = 7.5 Hz, 2H), 3.62 (s, 3H), 3.26 (t, J = 8.0 Hz, 2H), 2.38–2.24 (m, 5H); ¹³C NMR (101 MHz, CDCl₃) δ 174.56, 156.52, 143.87, 135.43, 119.37, 102.26, 52.03, 32.87, 28.30, 19.46, 12.75; HRMS (ESI): calcd for C₁₉H₁₉F₃N₃O [M + H]⁺: 220.0908, found 220.0903.

1,2-Dimethyl-6,7,8,9-tetrahydropyrido[1,2- a ]pyrrolo[2,3- d ]pyrimidine-4(1 H )-thione (13b). Yield 76%, yellow solid, m.p. 184–186°C. ¹H NMR (400 MHz, CDCl₃) δ 6.57 (s, 1H), 4.70 (t, J = 6.3 Hz, 2H), 3.62 (s, 4H), 3.04 (t, J = 6.8 Hz, 2H), 2.35 (s, 3H), 2.02 (p, J = 6.6, 6.1 Hz, 2H), 1.94 (p, J = 6.6 Hz, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 177.32, 153.50, 141.87, 135.61, 120.14, 103.03, 47.84, 32.47, 28.04, 22.46, 18.92, 12.70; HRMS (ESI): calcd for C₁₉H₁₉F₃N₃O [M + H]⁺: 234.1065, found 234.1059.

1,2-Dimethyl-1,6,7,8,9,10-hexahydro-4 H -pyrrolo[2',3':4,5]pyrimido[1,2- a ]azepine-4-thione (13c). Yield 80%, yellow solid, m.p. 223–224°C. ¹H NMR (400 MHz, CDCl₃) δ 6.54 (s, 1H), 5.11 (s, 2H), 3.61 (s, 3H), 3.21–3.13 (m, 2H), 2.34 (s, 3H), 1.84 (s, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 177.79, 157.73, 141.67, 135.82, 119.80, 103.60, 49.38, 38.09, 29.19, 28.03, 26.63, 25.44, 12.65; HRMS (ESI): calcd for C₁₉H₁₉F₃N₃O [M + H]⁺: 248.1221, found 248.1217.

1,2,3-Trimethyl-1,6,7,8-tetrahydro-4 H -dipyrrolo[1,2- a:2',3'-d]pyrimidine-4-thione (13d). Yield 79%, yellow solid, m.p. 258–260°C. ¹H NMR (400 MHz, CDCl₃) δ 4.52 (t, J = 7.2 Hz, 2H), 3.60 (s, 3H), 3.23 (t, J = 8.0 Hz, 2H), 2.57 (s, 3H), 2.34–2.21 (m, 5H); ¹³C NMR (101 MHz, CDCl₃) δ 175.32, 156.12, 143.61, 131.00, 117.52, 111.84, 51.87, 32.89, 28.24, 19.32, 10.98, 9.84; HRMS (ESI): calcd for C₁₉H₁₉F₃N₃O [M + H]⁺: 234.1065, found 234.1060.

1,2,3-Trimethyl-6,7,8,9-tetrahydropyrido[1,2- a ]pyrrolo[2,3-d]pyrimidine-4(1 H )-thione (13e). Yield 82%, yellow solid, m.p. 179–180°C. ¹H NMR (600 MHz, CDCl₃) δ 4.04 (t, J = 4.2 Hz, 2H), 3.58 (s, 3H), 2.90 (t, J = 6.7 Hz, 2H), 2.36 (s, 3H), 2.21 (s, 3H), 1.94 (p, J = 6.1 Hz, 2H), 1.88 (p, J = 6.2 Hz, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 159.64, 152.30, 146.01, 127.29, 109.59, 104.28, 41.00, 31.71, 28.11, 22.38, 19.48, 9.74, 9.51; HRMS (ESI): calcd for C₁₉H₁₉F₃N₃O [M + H]⁺: 248.1221, found 248.1216.

1,2,3-Trimethyl-1,6,7,8,9,10-hexahydro-4 H -pyrrolo[2',3':4,5]pyrimido[1,2- a ]azepine-4-thione (13f). Yield 86%, yellow solid, m.p. 138–140°C. ¹H NMR (400 MHz, CDCl₃) δ 5.10 (s, 2H), 3.59 (s, 3H), 3.14 (d, J = 7.2 Hz, 2H), 2.58 (s, 3H), 2.24 (s, 3H), 1.83 (s, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 178.56, 157.39, 141.51, 131.30, 117.94, 112.38, 48.39, 38.16, 29.16, 28.01, 26.60, 25.50, 11.41, 9.91; HRMS (ESI): calcd for C₁₉H₁₉F₃N₃O [M + H]⁺: 262.1378, found 262.1372.

1-Methyl-2-phenyl-1,6,7,8-tetrahydro-4 H -dipyrrolo[1,2- a:2',3'-d]pyrimidine-4-thione (13g). Yield 88%, yellow solid, m.p. 195–196°C. ¹H NMR (400 MHz, CDCl₃) δ 7.52–7.37 (m, 5H), 6.90 (s, 1H), 4.58 (t, J = 7.5 Hz, 2H), 3.75 (s, 3H), 3.31 (t, J = 8.0 Hz, 2H), 2.34 (p, J = 7.9 Hz, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 175.75, 157.28, 144.85, 139.68, 131.41, 128.86, 128.72, 128.38, 119.77, 104.01, 52.09, 33.00, 30.28, 19.45; HRMS (ESI): calcd for C₁₉H₁₉F₃N₃O [M + H]⁺: 282.1065, found 282.1060.

1-Methyl-2-phenyl-6,7,8,9-tetrahydropyrido[1,2- a ]pyrrolo[2,3- d ]pyrimidine-4(1 H )-thione (13h). Yield 87%, yellow solid, m.p. 157–158°C. ¹H NMR (400 MHz, CDCl₃) δ 7.53–7.37 (m, 5H), 4.71 (t, J = 6.1 Hz, 2H), 3.74 (s, 3H), 3.09 (t, J = 6.8 Hz, 2H), 2.05 (p, J = 6.5 Hz, 2H), 1.96 (p, J = 6.6 Hz, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 178.52, 154.30, 142.79, 139.80, 131.45, 128.84, 128.71, 128.36, 120.49, 104.82, 47.94, 32.59, 29.98, 22.47, 18.92; HRMS (ESI): calcd for C₁₉H₁₉F₃N₃O [M + H]⁺: 296.1221, found 296.1216.

1-Methyl-2-phenyl-1,6,7,8,9,10-hexahydro-4 H -pyrrolo[2',3':4,5]pyrimido[1,2- a ]azepine-4-thione (13i). Yield 90%, yellow solid, m.p. 140–141°C. ¹H NMR (400 MHz, CDCl₃) δ 7.52–7.38 (m, 5H), 6.88 (s, 1H), 5.19–5.10 (m, 2H), 3.74 (s, 3H), 3.26–3.18 (m, 2H), 1.87 (s, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 179.00, 158.51, 142.60, 140.02, 131.42, 128.84, 128.71, 128.38, 120.17, 105.41, 49.44, 38.18, 30.00, 29.20, 26.64, 25.44; HRMS (ESI): calcd for C₁₉H₁₉F₃N₃O [M + H]⁺: 310.1378, found 310.1373.

2-(4-Fluorophenyl)-1-methyl-1,6,7,8-tetrahydro-4 H -dipyrrolo[1,2- a:2',3'-d]pyrimidine-4-thione (13j). Yield 94%, yellow solid, m.p. 230–232°C. ¹H NMR (400 MHz, CDCl₃) δ 7.46 (dd, J = 8.6, 5.3 Hz, 2H), 7.16 (t, J = 8.6 Hz, 2H), 6.86 (s, 1H), 4.57 (t, J = 7.5 Hz, 2H), 3.71 (s, 3H), 3.31 (t, J = 8.0 Hz, 2H), 2.34 (p, J = 7.9 Hz, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 175.83, 164.01, 161.54, 157.41, 144.76, 138.54, 130.72, 127.51, 119.69, 115.96, 115.75, 104.06, 52.09, 32.99, 30.16, 19.43; HRMS (ESI): calcd for C₁₉H₁₉F₃N₃O [M + H]⁺: 300.0971, found 300.0967.

2-(4-Fluorophenyl)-1-methyl-6,7,8,9-tetrahydropyrido[1,2- a ]pyrrolo[2,3- d ]pyrimidine-4(1 H )-thione (13k). Yield 94%, yellow solid, m.p. 179–180°C. ¹H NMR (400 MHz, CDCl₃) δ 7.45 (dd, J = 8.4, 5.4 Hz, 2H), 7.14 (t, J = 8.5 Hz, 2H), 6.85 (s, 1H), 4.68 (t, J = 6.1 Hz, 2H), 3.69 (s, 3H), 3.07 (t, J = 6.8 Hz, 2H), 2.03 (p, J = 6.4 Hz, 2H), 1.95 (p, J = 6.6 Hz, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 178.54, 163.97, 161.50, 154.43, 142.72, 138.64, 130.60, 127.54, 120.37, 115.94, 115.72, 104.80, 47.95, 32.59, 29.88, 22.44, 18.89; HRMS (ESI): calcd for C₁₉H₁₉F₃N₃O [M + H]⁺: 314.1127, found 314.1120.

2-(4-Fluorophenyl)-1-methyl-1,6,7,8,9,10-hexahydro-4 H -pyrrolo[2',3':4,5]pyrimido[1,2- a ]azepine-4-thione (13l). Yield 99%, yellow solid, m.p. 123–124°C. ¹H NMR (400 MHz, CDCl₃) δ 7.46 (dd, J = 8.4, 5.4 Hz, 2H), 7.16 (t, J = 8.5 Hz, 2H), 6.85 (s, 1H), 5.15 (s, 2H), 3.71 (s, 3H), 3.22 (s, 2H), 1.88 (s, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 179.09, 164.02, 161.55, 158.63, 142.56, 138.89, 130.71, 130.62, 127.53, 120.11, 115.96, 115.75, 105.46, 49.45, 38.20, 29.84, 29.20, 26.63, 25.43; HRMS (ESI): calcd for C₁₉H₁₉F₃N₃O [M + H]⁺: 328.1284, found 328.1279.

2-(4-Chlorophenyl)-1-methyl-1,6,7,8-tetrahydro-4 H -dipyrrolo[1,2- a:2',3'-d]pyrimidine-4-thione (13m). Yield 92%, yellow solid, m.p. 199–200°C. ¹H NMR (400 MHz, CDCl₃) δ 7.45–7.39 (m, 4H), 6.88 (s, 1H), 4.56 (t, J = 7.2 Hz, 2H), 3.72 (s, 3H), 3.31 (t, J = 8.0 Hz, 2H), 2.34 (p, J = 7.9 Hz, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 175.92, 157.55, 144.79, 138.30, 134.50, 130.01, 129.82, 129.01, 119.71, 104.34, 52.12, 32.99, 30.31, 19.40; HRMS (ESI): calcd for C₁₉H₁₉F₃N₃O [M + H]⁺: 316.0675, found 316.0672.

2-(4-Chlorophenyl)-1-methyl-6,7,8,9-tetrahydropyrido[1,2- a ]pyrrolo[2,3- d ]pyrimidine-4(1 H )-thione (13n). Yield 98%, yellow solid, m.p. 151–153°C. ¹H NMR (400 MHz, CDCl₃) δ 7.42 (s, 4H), 6.89 (s, 1H), 4.69 (t, J = 6.1 Hz, 2H), 3.72 (s, 3H), 3.08 (t, J = 6.7 Hz, 2H), 2.05 (p, J = 6.6 Hz, 2H), 1.96 (p, J = 6.5 Hz, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 178.72, 154.57, 142.80, 138.42, 134.47, 130.00, 129.88, 129.00, 120.43, 105.16, 47.99, 32.57, 30.05, 22.45, 18.88; HRMS (ESI): calcd for C₁₉H₁₉F₃N₃O [M + H]⁺: 330.0832, found 330.0826.

2-(4-Chlorophenyl)-1-methyl-1,6,7,8,9,10-hexahydro-4 H -pyrrolo[2',3':4,5]pyrimido[1,2- a ]azepine-4-thione (13o). Yield 98%, yellow solid, m.p. 164–166°C. ¹H NMR (400 MHz, CDCl₃) δ 7.42 (s, 4H), 6.86 (s, 1H), 5.13 (s, 2H), 3.71 (s, 3H), 3.21 (d, J = 6.0 Hz, 2H), 1.86 (s, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 179.18, 158.75, 142.69, 138.62, 134.48, 129.99, 129.86, 129.00, 120.10, 105.73, 49.43, 38.17, 29.99, 29.16, 26.61, 25.40; HRMS (ESI): calcd for C₁₉H₁₉F₃N₃O [M + H]⁺: 344.0988, found 344.0984.

2-(4-Bromophenyl)-1-methyl-1,6,7,8-tetrahydro-4 H -dipyrrolo[1,2- a:2',3'-d]pyrimidine-4-thione (13p). Yield 99%, yellow solid, m.p. 210–212°C. ¹H NMR (400 MHz, CDCl₃) δ 7.59 (d, J = 8.4 Hz, 2H), 7.36 (d, J = 8.4 Hz, 2H), 6.89 (s, 1H), 4.57 (t, J = 7.5 Hz, 2H), 3.73 (s, 3H), 3.31 (t, J = 8.0 Hz, 2H), 2.35 (p, J = 7.9 Hz, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 175.97, 157.55, 144.91, 138.31, 131.96, 130.30, 130.27, 122.70, 119.73, 104.37, 52.10, 33.00, 30.20, 19.41; HRMS (ESI): calcd for C₁₉H₁₉F₃N₃O [M + H]⁺: 360.0170, found 360.0170.

2-(4-Bromophenyl)-1-methyl-6,7,8,9-tetrahydropyrido[1,2- a ]pyrrolo[2,3- d ]pyrimidine-4(1 H )-thione (13q). Yield 99%, yellow solid, m.p. 196–197°C. ¹H NMR (400 MHz, CDCl₃) δ 7.58 (d, J = 8.3 Hz, 2H), 7.36 (d, J = 8.3 Hz, 2H), 6.90 (s, 1H), 4.69 (t, J = 6.3 Hz, 2H), 3.71 (s, 3H), 3.08 (t, J = 6.8 Hz, 2H), 2.05 (p, J = 7.0 Hz, 2H), 1.96 (p, J = 6.6 Hz, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 178.74, 154.56, 142.94, 138.41, 131.93, 130.36, 130.25, 122.66, 120.42, 105.15, 47.97, 32.61, 30.01, 22.45, 18.89; HRMS (ESI): calcd for C₁₉H₁₉F₃N₃O [M + H]⁺: 374.0327, found 374.0300.

2-(4-Bromophenyl)-1-methyl-1,6,7,8,9,10-hexahydro-4 H -pyrrolo[2',3':4,5]pyrimido[1,2- a ]azepine-4-thione (13r). Yield 99%, yellow solid, m.p. 188–190°C. ¹H NMR (400 MHz, CDCl₃) δ 7.58 (d, J = 8.3 Hz, 2H), 7.36 (d, J = 8.4 Hz, 2H), 6.87 (s, 1H), 5.13 (s, 2H), 3.71 (s, 3H), 3.21 (d, J = 6.9 Hz, 2H), 1.87 (s, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 179.21, 158.77, 142.75, 138.63, 131.95, 130.33, 130.25, 122.68, 120.12, 105.75, 49.43, 38.19, 29.98, 29.17, 26.62, 25.41; HRMS (ESI): calcd for C₁₉H₁₉F₃N₃O [M + H]⁺: 388.0483, found 388.0478.

1-Methyl-2-( p -tolyl)-1,6,7,8-tetrahydro-4 H -dipyrrolo[1,2- a:2',3'-d]pyrimidine-4-thione (13s). Yield 99%, yellow solid, m.p. 200–202°C. ¹H NMR (400 MHz, CDCl₃) δ 7.39 (d, J = 8.0 Hz, 2H), 7.27 (d, J = 7.9 Hz, 2H), 6.86 (s, 1H), 4.57 (t, J = 7.5 Hz, 2H), 3.73 (s, 3H), 3.31 (t, J = 8.0 Hz, 2H), 2.41 (s, 3H), 2.34 (p, J = 7.9 Hz, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 175.51, 157.15, 144.74, 139.81, 138.39, 129.43, 128.74, 128.48, 119.73, 103.57, 52.09, 32.99, 30.24, 21.32, 19.44; HRMS (ESI): calcd for C₁₉H₁₉F₃N₃O [M + H]⁺: 296.1221, found 296.1215.

1-Methyl-2-( p -tolyl)-6,7,8,9-tetrahydropyrido[1,2- a ]pyrrolo[2,3- d ]pyrimidine-4(1 H )-thione (13t). Yield 95%, yellow solid, m.p. 159–161°C. ¹H NMR (400 MHz, CDCl₃) δ 7.39 (d, J = 8.0 Hz, 2H), 7.27 (d, J = 7.9 Hz, 2H), 6.87 (s, 1H), 4.71 (t, J = 6.1 Hz, 2H), 3.72 (s, 3H), 3.08 (t, J = 6.7 Hz, 2H), 2.41 (s, 3H), 2.05 (p, J = 6.4 Hz, 2H), 1.96 (p, J = 6.5 Hz, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 178.24, 154.18, 142.71, 139.92, 138.36, 129.42, 128.71, 128.51, 120.44, 104.36, 47.92, 32.57, 30.00, 22.47, 21.33, 18.91; HRMS (ESI): calcd for C₁₉H₁₉F₃N₃O [M + H]⁺: 310.0378, found 310.1371.

1-Methyl-2-( p -tolyl)-1,6,7,8,9,10-hexahydro-4 H -pyrrolo[2',3':4,5]pyrimido[1,2- a ]azepine-4-thione (13u). Yield 99%, yellow solid, m.p. 149–151°C. ¹H NMR (400 MHz, CDCl₃) δ 7.39 (d, J = 8.0 Hz, 2H), 7.26 (d, J = 7.9 Hz, 2H), 6.85 (s, 1H), 5.14 (s, 2H), 3.72 (s, 3H), 3.21 (s, 2H), 2.41 (s, 3H), 1.87 (s, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 178.76, 158.36, 142.50, 140.14, 138.38, 128.72, 128.49, 120.15, 104.97, 49.41, 38.15, 29.96, 29.18, 26.64, 25.44, 21.32; HRMS (ESI): calcd for C₁₉H₁₉F₃N₃O [M + H]⁺: 324.1534, found 324.1528.

2-(4-Methoxyphenyl)-1-methyl-1,6,7,8-tetrahydro-4 H -dipyrrolo[1,2- a:2',3'-d]pyrimidine-4-thione (13v). Yield 99%, yellow solid, m.p. 224–225°C. ¹H NMR (400 MHz, CDCl₃) δ 7.41 (d, J = 8.6 Hz, 2H), 6.98 (d, J = 8.6 Hz, 2H), 6.82 (s, 1H), 4.56 (t, J = 7.5 Hz, 2H), 3.85 (s, 3H), 3.71 (s, 3H), 3.30 (t, J = 8.0 Hz, 2H), 2.33 (p, J = 7.9 Hz, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 175.39, 159.76, 157.05, 144.53, 139.64, 130.20, 123.77, 119.77, 114.17, 103.27, 55.33, 52.11, 32.97, 30.12, 19.44; HRMS (ESI): calcd for C₁₉H₁₉F₃N₃O [M + H]⁺: 312.1171, found 312.1166.

2-(4-Methoxyphenyl)-1-methyl-6,7,8,9-tetrahydropyrido[1,2- a ]pyrrolo[2,3- d ]pyrimidine-4(1 H )-thione (13w). Yield 95%, yellow solid, m.p. 178–179°C. ¹H NMR (400 MHz, CDCl₃) δ 7.42 (d, J = 8.6 Hz, 2H), 6.98 (d, J = 8.7 Hz, 2H), 6.84 (s, 1H), 4.71 (t, J = 6.1 Hz, 2H), 3.86 (s, 3H), 3.71 (s, 3H), 3.08 (t, J = 6.8 Hz, 2H), 2.05 (p, J = 6.4 Hz, 2H), 1.96 (p, J = 6.6 Hz, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 178.15, 159.74, 154.06, 142.61, 139.77, 130.19, 123.84, 120.51, 114.16, 104.06, 55.39, 47.93, 32.56, 29.91, 22.47, 18.93; HRMS (ESI): calcd for C₁₉H₁₉F₃N₃O [M + H]⁺: 326.1327, found 326.1321.

2-(4-Methoxyphenyl)-1-methyl-1,6,7,8,9,10-hexahydro-4 H -pyrrolo[2',3':4,5]pyrimido[1,2- a ]azepine-4-thione (13x). Yield 91%, yellow solid, m.p. 220–221°C. ¹H NMR (400 MHz, CDCl₃) δ 7.40 (d, J = 8.7 Hz, 2H), 6.97 (d, J = 8.7 Hz, 2H), 6.80 (s, 1H), 5.13 (s, 2H), 3.84 (s, 3H), 3.69 (s, 3H), 3.20 (d, J = 5.6 Hz, 2H), 1.86 (s, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 178.60, 159.75, 158.27, 142.42, 139.96, 130.16, 123.79, 120.15, 114.16, 104.64, 55.33, 49.41, 38.16, 29.89, 29.19, 26.65, 25.44; HRMS (ESI): calcd for C₁₉H₁₉F₃N₃O [M + H]⁺: 340.1484, found 340.1480.

1-Methyl-2-(4-(trifluoromethyl)phenyl)-1,6,7,8-tetrahydro-4 H -dipyrrolo[1,2- a:2',3'-d]pyrimidine-4-thione (13y). Yield 97%, yellow solid, m.p. 168–169°C. ¹H NMR (400 MHz, CDCl₃) δ 7.71 (d, J = 8.2 Hz, 2H), 7.61 (d, J = 8.2 Hz, 2H), 6.94 (s, 1H), 4.54 (t, J = 7.6, 7.2 Hz, 2H), 3.74 (s, 3H), 3.30 (t, J = 8.0 Hz, 2H), 2.34 (p, J = 7.9 Hz, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 176.21, 157.89, 145.22, 137.78, 134.92, 129.97, 128.89, 125.75, 122.60, 119.66, 105.13, 52.11, 33.01, 30.38, 19.37; HRMS (ESI): calcd for C₁₉H₁₉F₃N₃O [M + H]⁺: 350.0939, found 350.0933.

1-Methyl-2-(4-(trifluoromethyl)phenyl)-6,7,8,9-tetrahydropyrido[1,2- a ]pyrrolo[2,3- d ]pyrimidine-4(1 H )-thione (13z). Yield 88%, yellow solid, m.p. 178–179°C. ¹H NMR (400 MHz, CDCl₃) δ 7.70 (d, J = 8.2 Hz, 2H), 7.61 (d, J = 8.1 Hz, 2H), 6.95 (s, 1H), 4.68 (t, J = 6.2 Hz, 2H), 3.74 (s, 3H), 3.08 (t, J = 6.8 Hz, 2H), 2.04 (p, J = 6.4 Hz, 2H), 1.95 (p, J = 6.6 Hz, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 179.04, 154.89, 143.17, 137.90, 135.00, 129.94, 128.87, 125.73, 122.62, 120.38, 105.98, 48.00, 32.63, 30.14, 22.43, 18.86; HRMS (ESI): calcd for C₁₉H₁₉F₃N₃O [M + H]⁺: 364.1095, found 364.1089.

1-Methyl-2-(4-(trifluoromethyl)phenyl)-1,6,7,8,9,10-hexahydro-4 H -pyrrolo[2',3':4,5]pyrimido[1,2- a ]azepine-4-thione (13aa). Yield 99%, yellow solid, m.p. 175–177°C. ¹H NMR (400 MHz, CDCl₃) δ 7.70 (d, J = 8.2 Hz, 2H), 7.60 (d, J = 8.2 Hz, 2H), 6.92 (s, 1H), 5.16–5.06 (m, 2H), 3.73 (s, 3H), 3.25–3.15 (m, 2H), 1.85 (s, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 179.45, 159.08, 142.95, 138.10, 134.94, 129.93, 128.88, 125.69, 122.61, 120.05, 106.54, 49.42, 38.17, 30.09, 29.12, 26.58, 25.37; HRMS (ESI): calcd for C₁₉H₁₉F₃N₃O [M + H]⁺: 378.1252, found 378.1248.

4.2. Biology

Materials

Doxorubicin was purchased from BBI Inc. (Shanghai, China). The human cancer HeLa, MCF-7, and HT-29 cell lines were obtained from Chinese Type Culture Collection, CAS (Shanghai, China).

Cell cultures

Human HeLa, MCF-7, and HT-29 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) with 4.5 g/L glucose and 0.37% sodium bicarbonate (Gibco, Rockville, MD, USA). All cell culture media contained with 10% FBS and antibiotic mix (1×100 µM penicillin A and 100 µM of streptomycin) and were grown at 37°C in a humidified incubator (Binder, Germany) containing 95% air / 5% CO₂ and have been fed every 3–4 days [51].

Ethical Approval

Not applicable

Competing interests

No potential conflict of interest was reported by the authors.

Authors' contributions

B.S. performed the synthesis, biological experiments, and compounds analysis part. L.F. performed the design of synthesis, software, and compounds analysis part. K.B. designed a synthesis and wrote the main manuscript text. R.K. revised the manuscript. H.A.A. supervised the research and revised the main manuscript. J.Z. supervised the research and revised the main manuscript. All authors reviewed the manuscript.

Funding

This work was financially supported by the National Key R&D Program of China (No. 2020YFE0205600), and by “CAM Resources Data Base” in National Basic Science Data Center (No. NBSDC-DB-19).

Availability of data and materials

Not applicable

Z. Li, W. Si, W. Jin, Z. Yuan, Y. Chen and L. Fu Drug Discov. Today 27, 8 (2022)
S. Senapati, A.K. Mahanta, S. Kumar and P. Maiti Signal Transduct. Target. Ther. 3, 1 (2018)
K.O. Alfarouk, C.M. Stock, S. Taylor, M. Walsh, A.K. Muddathir, D. Verduzco, A.H.H. Bashir, O.Y. Mohammed, G.O. Elhassan, S. Harguindey, S.J. Reshkin, M.E. Ibrahim and C. Rauch Cancer Cell Int. 15, 1 (2015)
K.A. Wesnes Dialogues Clin. Neurosci. 2, 3 (2000)
S. Dagenais, L. Russo, A. Madsen, J. Webster and L. Becnel Clin. Pharmacol. Ther. 111, 1 (2022)
F. Liu, X. Hou, L.F. Nie, K. Bozorov, M. Decker and G. Huang SynOpen 02, 02 (2018)
M. Szewc, E. Radzikowska-Bűchner, P. Wdowiak, J. Kozak, P. Kuszta, E. Niezabitowska, J. Matysiak, K. Kubiński and M. Masłyk Int. J. Mol. Sci. 23, 5 (2022)
D. Cunningham, N. Starling, S. Rao, T. Iveson, M. Nicolson, F. Coxon, G. Middleton, F. Daniel, J. Oates and A.R. Norman N. Engl. J. Med. 358, 1 (2008)
H. Kantarjlan, J.P.J. Issa, C.S. Rosenfeld, J.M. Bennett, M. Albitar, J. DiPersio, V. Klimek, J. Slack, C. De Castro, F. Ravandi, R. Helmer Iii, L. Shen, S.D. Nimer, R. Leavitt, A. Raza and H. Saba Cancer 106, 8 (2006)
W. Plunkett, P. Huang, Y.Z. Xu, V. Heinemann, R. Grunewald and V. Gandhi, in Seminars in Oncology(1995), pp. 3–10
C. Kelly, N. Bhuva, M. Harrison, A. Buckley and M. Saunders Eur. J. Cancer 49, 10 (2013)
M. Hu, P. Huang, Y. Wang, Y. Su, L. Zhou, X. Zhu and D. Yan Bioconjugate Chem. 26, 12 (2015)
T. Hata, K. Hagihara, A. Tsutsui, H. Akamatsu, M. Ohue, T. Shingai, M. Tei, M. Ikenaga, H.M. Kim, H. Osawa, H. Takemoto, K. Konishi, M. Uemura, C. Matsuda, T. Mizushima, K. Murata, Y. Ohno, Y. Doki and H. Eguchi Oncologist 26, 5 (2021)
U. Anand, A. Dey, A.K.S. Chandel, R. Sanyal, A. Mishra, D.K. Pandey, V. De Falco, A. Upadhyay, R. Kandimalla, A. Chaudhary, J.K. Dhanjal, S. Dewanjee, J. Vallamkondu and J.M. Pérez de la Lastra Genes Dis., https://doi.org/10.1016/j.gendis.2022.02.007, (2022)
M.A. Karimi Zarchi, F. Hajati and B.F. Mirjalili Res. Chem. Intermed. 48, 8 (2022)
M.S. Salem, S.A.M. Al-Mabrook and M.A.E.M. El-Hashash J. Sulfur Chem. 42, 3 (2021)
A. Saeed, M.N. Mustafa, M. Zain-ul-Abideen, G. Shabir, M.F. Erben and U. Flörke J. Sulfur Chem. 40, 3 (2019)
C. Chen, D. Pung, V. Leong, V. Hebbar, G. Shen, S. Nair, W. Li and A.N. Tony Kong Free Radic. Biol. Med. 37, 10 (2004)
R. Rohac, P. Amara, A. Benjdia, L. Martin, P. Ruffié, A. Favier, O. Berteau, J.M. Mouesca, J.C. Fontecilla-Camps and Y. Nicolet Nat. Chem. 8, 5 (2016)
D.M. Davenport and M.J. Wargovich Food Chem. Toxicol. 43, 12 (2005)
M.P. Jain, S.K. Koul, K.L. Dhar and C.K. Atal Phytochemistry 19, 8 (1980)
Y. Zeng, L. Nie, L. Liu, C. Niu, Y. Li, K. Bozorov, J. Zhao, J. Shen and H.A. Aisa J. Heterocycl. Chem. 59, 6 (2022)
Y. Zeng, L. Nie, C. Niu, A. Mamatjan, K. Bozorov, J. Zhao and H.A. Aisa Chin. J. Org. Chem. 42, 2 (2022)
R. Sharma, E. Chatterjee, J. Mathew, S. Sharma, N.V. Rao, C.H. Pan, S.B. Lee, A. Dhingra, A.S. Grewal, J.P. Liou, S.K. Guru and K. Nepali Eur. J. Med. Chem. 240, (2022)
H. Du, X. Liu, J. Xie and F. Ma ACS Chem. Neurosci. 10, 5 (2019)
S. Manzoor, M.T. Gabr, B. Rasool, K. Pal and N. Hoda Bioorg. Chem. 116, (2021)
J.H. Tan, T.M. Ou, J.Q. Hou, Y.J. Lu, S.L. Huang, H.B. Luo, J.Y. Wu, Z.S. Huang, K.Y. Wong and L.Q. Gu J. Med. Chem. 52, 9 (2009)
R. Kaur, S.K. Manjal, R.K. Rawal and K. Kumar Bioorg. Med. Chem. 25, 17 (2017)
A. Cagir, S.H. Jones, R. Gao, B.M. Eisenhauer and S.M. Hecht J. Am. Chem. Soc. 125, 45 (2003)
K.M. Tian, J.J. Li and S.W. Xu Pharmacol. Res. 141, (2019)
J. Jiang and C. Hu Molecules 14, 5 (2009)
Y. Zeng, L. Nie, K. Bozorov, Z. Ruzi, B. Song, J. Zhao and H.A. Aisa J. Heterocycl. Chem. 59, 3 (2022)
H. Guo, L. Nie, K. Bozorov, H.A. Aisa and J. Zhao Heterocycles 104, 6 (2022)
L.F. Nie, K. Bozorov, G. Huang, J. Zhao, C. Niu and H.A. Aisa Phosphorus Sulfur Silicon Relat. Elem. 193, 10 (2018)
L.F. Nie, G. Huang, K. Bozorov, J. Zhao, C. Niu, S.S. Sagdullaev and H.A. Aisa Heterocycl. Commun. 24, 1 (2018)
A. Nasrullaev, K. Bozorov, K. Bobakulov, J. Zhao, L.F. Nie, K.K. Turgunov, B. Elmuradov and H.A. Aisa Res. Chem. Intermed. 45, 4 (2019)
B.Z. Elmuradov, K.A. Bozorov and K.M. Shakhidoyatov Chem. Heterocycl. Compd. 46, 11 (2011)
K. Bozorov, J.Y. Zhao and H.A. Aisa Arkivoc 2017, 1 (2016)
K.A. Bozorov, N.Z. Mamadalieva, B.Z. Elmuradov, D. Triggiani, D. Egamberdieva, A. Tiezzi, H.A. Aisa and K.M. Shakhidoyatov J. Chem. 2013, (2013)
T. Yamamoto and M. Muraoka Heterocycles 91, 12 (2015)
J.W. Scheeren, P.H.J. Ooms and R.J.F. Nivard Synthesis 1973, 3 (1973)
T. Ozturk, E. Ertas and O. Mert Chem. Rev. 107, 11 (2007)
M.P. Cava and M.I. Levinson Tetrahedron 41, 22 (1985)
M. Jesberger, T.P. Davis and L. Barner Synthesis, 10.1055/s-2003-41447, 13 (2003)
T.J. Curphey J. Org. Chem. 67, 18 (2002)
S.B. Bari and N.G. Haswani J. Saudi Chem. Soc. 21, (2017)
P. Thanigaimalai, K.-C. Lee, S.-C. Bang, J.-H. Lee, C.-Y. Yun, E. Roh, B.-Y. Hwang, Y. Kim and S.-H. Jung Bioorg. Med. Chem. 18, 3 (2010)
J.M. Khurana, D. Magoo, K. Aggarwal, N. Aggarwal, R. Kumar and C. Srivastava Eur. J. Med. Chem. 58, (2012)
F. Shibahara, R. Sugiura and T. Murai Org. Lett. 11, 14 (2009)
B. Song, L. Nie, K. Bozorov, R. Kuryazov, J. Zhao and H.A. Aisa Mol. Divers., (2022)
Z. Ruzi, L. Nie, K. Bozorov, J. Zhao and H.A. Aisa Arch. Pharm. 354, 9 (2021)

Table 1-2 is available in the Supplemental Files section.

Scheme 1-4 is available in supplementary section.

No competing interests reported.

TABLES.docx
SUPPORTINGINFORMATION.docx
S1.png
Scheme 1. Synthesis of furo[2,3-d]pyrimidinone 6a-6aa and pyrrolo[2,3-d]pyrimidinone 11a-11aa intermediates.
S2.png
Scheme 2. One-pot formation of pyrimidine-thiones 12g and 13g
S3.png
Scheme 3. A library of the synthesized tricyclic furo[2,3-d]pyrimidinthiones (12a-12aa).
S4.png
Scheme 4. A library of the synthesized tricyclic pyrrolo[2,3-d]pyrimidinthiones (13a-13aa).
GA.png
GRAPHICAL ABSTRACT

Download PDF

Editorial decision: Major revision
12 Nov, 2022
Reviews received at journal
07 Nov, 2022
Reviewers agreed at journal
31 Oct, 2022
Reviewers invited by journal
17 Oct, 2022
Editor assigned by journal
04 Oct, 2022
Submission checks completed at journal
04 Oct, 2022
First submitted to journal
30 Sep, 2022

You are reading this latest preprint version

Parallel synthesis of condensed pyrimidine-thiones and their antitumor activities

Status:

Version 1

Abstract

Figures

1. Introduction

2. Results And Discussion

2.1. Chemistry

2.2. Antitumor activity

3. Conclusion

4. Experimental Section

4.1. Chemistry

4.2. Biology

Declarations

References

Tables

Scheme

Additional Declarations

Supplementary Files

Status:

Version 1